Home
/
Amphastar Pharmaceuticals, Inc.
/
Financials
/
Quarterly
Amphastar Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Amphastar Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$191.84M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$174.41M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$170.53M
May 8, 2025
Q3
2025
Sep 30, 2024
$191.21M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$182.39M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$171.84M
May 8, 2025
Q3
2024
Sep 30, 2023
$180.56M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$145.71M
Aug 9, 2024
Q1
2024
Mar 31, 2023
$140.02M
May 10, 2024
Q3
2023
Sep 30, 2022
$120.13M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$123.47M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$120.37M
May 9, 2023
Q3
2022
Sep 30, 2021
$112.20M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$101.66M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$103.02M
May 10, 2022
Q3
2021
Sep 30, 2020
$83.43M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$85.81M
Aug 9, 2021
Q1
2021
Mar 31, 2020
$84.69M
May 7, 2021
Q3
2020
Sep 30, 2019
$80.14M
Nov 6, 2020
Q2
2020
Jun 30, 2019
$79.05M
Aug 7, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Sep 30, 2018
$75.54M
Nov 9, 2018
Q2
2018
Jun 30, 2018
$71.04M
Aug 9, 2018
Q1
2018
Mar 31, 2018
$58.39M
May 10, 2018
Q3
2018
Sep 30, 2017
$57.92M
Nov 9, 2018
Q2
2018
Jun 30, 2017
$65.19M
Aug 9, 2018
Q1
2018
Mar 31, 2017
$56.67M
May 10, 2018
Q3
2017
Sep 30, 2016
$64.22M
Nov 9, 2017
Q2
2017
Jun 30, 2016
$68.03M
Aug 9, 2017
Q1
2017
Mar 31, 2016
$59.37M
May 10, 2017
Q3
2016
Sep 30, 2015
$63.87M
Nov 9, 2016
Q2
2016
Jun 30, 2015
$53.85M
Aug 9, 2016
Q1
2016
Mar 31, 2015
$56.89M
May 10, 2016
Q3
2015
Sep 30, 2014
$59.71M
Nov 13, 2015
Q2
2015
Jun 30, 2014
$49.00M
Aug 13, 2015
Q1
2015
Mar 31, 2014
$45.87M
May 14, 2015
Q3
2014
Sep 30, 2013
$59.32M
Nov 13, 2014
Q2
2014
Jun 30, 2013
$62.52M
Aug 13, 2014
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$17.35M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$31.03M
Aug 7, 2025
Q3
2025
Jun 30, 2025
$31.03M
Nov 6, 2025
Q2
2025
Mar 31, 2025
$25.29M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$25.29M
May 8, 2025
Q3
2025
Mar 31, 2025
$25.29M
Nov 6, 2025
Q3
2025
Sep 30, 2024
$40.43M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$37.95M
Aug 7, 2025
Q3
2025
Jun 30, 2024
$37.95M
Nov 6, 2025
Q2
2025
Mar 31, 2024
$43.18M
Aug 7, 2025
Q3
2025
Mar 31, 2024
$43.18M
Nov 6, 2025
Q1
2025
Mar 31, 2024
$43.18M
May 8, 2025
Q3
2024
Sep 30, 2023
$49.22M
Nov 7, 2024
Q3
2024
Jun 30, 2023
$26.12M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$26.12M
Aug 9, 2024
Q1
2024
Mar 31, 2023
$26.03M
May 10, 2024
Q3
2024
Mar 31, 2023
$26.03M
Nov 7, 2024
Q2
2024
Mar 31, 2023
$26.03M
Aug 9, 2024
Q3
2023
Sep 30, 2022
$15.87M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$17.35M
Aug 9, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$25.32M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$42.18M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$37.29M
May 8, 2025
Q3
2025
Sep 30, 2024
$57.05M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$55.22M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$48.01M
May 8, 2025
Q3
2024
Sep 30, 2023
$72.68M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$36.90M
Aug 9, 2024
Q1
2024
Mar 31, 2023
$33.43M
May 10, 2024
Q3
2023
Sep 30, 2022
$23.23M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$24.82M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$21.61M
May 9, 2023
Q3
2022
Sep 30, 2021
$24.77M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$10.56M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$10.31M
May 10, 2022
Q3
2021
Sep 30, 2020
$3.52M
Nov 9, 2021
Q2
2021
Jun 30, 2020
($2.92M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
$7.48M
May 7, 2021
Q3
2020
Sep 30, 2019
$2.40M
Nov 6, 2020
Q2
2020
Jun 30, 2019
$973.0K
Aug 7, 2020